Harrow, Inc.

US$26.89As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:HROWHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 25.85%
Div yield —
ROE (116.07%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.17
PE TTM —
TSR TTM (28.81%)
Mkt cap US$1.008B
ROIC (1.19%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$28
5.39%
27.96%
Hold 11|12|5|10|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.29
0.31
0.30
0.32
14.45%
21.89%
4.68%
13.79%
Revenue$M
124.3
130.9
133.0
138.3
11.73%
16.80%
13.10%
16.18%
Peers (US$1.008B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.192
(1.808)
(1.532)
EBIT/Intx
0.220
0.138
0.138
Own earn%
10.23
97.18
115.79
Sh yield%
15.23
29.44
31.88
Owners
Insiders/Inst%
7.66
33.10
Short interest%
5.38
SBC / revenue%
3.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
27–35
$1 testx
—
Incr. ROIC%
10